A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Boehringer Filed NDA for Afatinib in Japan: Chairman
April 26, 2013
-
BUSINESS Edoxaban Will Be Key to Achieving Targets in Daiichi Sankyo’s New 5-Year Business Plan
April 26, 2013
-
ORGANIZATION Itsuro Yoshida of Towa Pharmaceutical Expected to Take Over as Next President of JGA
April 25, 2013
-
REGULATORY Bill to Amend PAL Will Be Submitted to Diet in May, as Instructed by PM Abe: Mr Akagawa of PFSB
April 25, 2013
-
ACADEMIA RA Treatment Guidelines to Reflect Patients’ Values and Economic Considerations as Well as Evidence
April 24, 2013
-
ACADEMIA New COPD Guidelines Recommend LAMA, LABA on Equal Footing
April 23, 2013
-
BUSINESS Pfizer-Mylan Pair’s Japan Generic Share at 2.8%, Aspire for Bigger Slice of Market
April 22, 2013
-
BUSINESS Tug-of-War over “Conflicts of Interest” (2): “Diovan Scandal” Brings Renewed Attention to COI
April 19, 2013
-
BUSINESS Novo Nordisk Ups Efforts in Basal Insulin Market, Pits Tresiba against Lantus
April 18, 2013
-
ORGANIZATION Tug-of-War over “Conflicts of Interest” (1): Drug Makers, Doctors Remain Divided
April 18, 2013
-
BUSINESS Teijin Pharma Hopes to Derive 50%-Plus of Sales from New Drugs by around 2016: Pres. Uno
April 17, 2013
-
REGULATORY Growing Concern Over Return to Brand Names for Generics with Advent of Generic Versions of Combination Drugs
April 16, 2013
-
REGULATORY Supreme Court Rejects Damage Claims in Iressa Suits; Govt, AZ Win 8-Year Battle
April 15, 2013
-
BUSINESS 11 Drug Makers to Increase, 11 to Decrease Hiring Next Year; Mid-Sized Companies Most Optimistic on Hiring
April 15, 2013
-
REGULATORY Generic Roadmap: CSIMC Bill Payer Rep Says New 60% Target Could “Decelerate” Shift
April 12, 2013
-
BUSINESS Eisai Announces Organizational Reforms; “We Won’t Allow Generics to Overwhelm AD Market”: President Naito
April 12, 2013
-
BUSINESS Shire Enters Japan Full Force, Six Products to Be Launched in Five Years
April 11, 2013
-
BUSINESS Amgen Plans New Product Debuts in Japan by 2016, Pins Hopes on Hyperlipidemia Drug
April 10, 2013
-
BUSINESS Rubella Epidemic Triggers Vaccine Shipment Adjustments at Drug Makers
April 9, 2013
-
REGULATORY MHLW Unveils Generic Roadmap, Aims for 60%-Share by FY2017
April 8, 2013
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…